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ABSTRACT
DEVELOPMENT OF A MICROFLUIDIC VISCOELASTIC HEMOSTATIC ASSAY
FOR REAL-TIME VISCOSITY MEASUREMENTS OF BLOOD

By
Shay Kent
August 2021

Thesis supervised by Dr. Melikhan Tanyeri
Blood coagulation disorders are malfunctions in the body’s ability to control blood
clotting. It can result in either insufficient clotting causing an increased risk of bleeding or
excessive clotting obstructing blood flow. The rapid and accurate diagnosis of
coagulopathies is an important, unmet need in the clinical setting. Rapidly identifying the
source of bleeding, either acquired or inherited, is critical to reduce the risk of major blood
loss and deliver personalized hemostatic therapies. Viscoelastic hemostatic assays, or
VHAs, deliver an effective solution to the diagnosis of coagulopathies by evaluating global
hemostatic function using whole blood rather than plasma. VHAs are functional blood tests
that monitor all phases of coagulation by measuring the viscoelastic properties of blood
during clot formation and degradation to help determine the root cause of bleeding.
Presently, the two major commercialized VHA techniques are the thromboelastometry
(TEM) and the thromboelastography (TEG). These two instruments, however, have a high
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acquisition cost, bulky benchtop size, and are mostly limited to use in surgical procedures.
Here, we aim to develop a microfluidic viscoelastic hemostatic assay (µVHA) to facilitate
point-of-care hemostatic tests based on digital microfluidics where whole blood samples
are partitioned into nanoliter sized emulsion droplets. These devices have been fabricated
using soft lithography techniques and are capable of determining viscoelastic properties of
coagulating blood as a function of time. We employ digital microfluidics where blood
samples are split into nanoliter sized droplets within a microchannel under constant
pressure, and viscoelastic properties of blood are deduced from droplet properties such as
droplet length and inter-droplet distance. The length of the droplets is correlated with
aqueous phase viscosity at high ratios of aqueous-to-oil inlet pressure. Here, we
demonstrate a proof-of-concept blood coagulation analysis device that can potentially
deduce viscoelastic properties of whole blood under low shear conditions, thereby
providing information about global hemostatic function from the beginning of clot
formation through clot retractions and fibrinolysis. These portable and low cost µVHAs
would ultimately reduce the footprint and overall cost, broaden potential applications
beyond emergency and surgical procedures and enable adoption by military medics for
field diagnosis of combat trauma patients.
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Chapter I
Introduction

1.1 Introduction
The rapid and accurate diagnosis and immediate initiation of treatment of
coagulopathies are an important, unmet need in the clinical setting to prevent unnecessary
mortality and morbidity [1]. In order to reduce the risk of major blood loss and deliver
personalized hemostatic therapies, it is critical to rapidly identify the source of bleeding,
either acquired or inherited. In the field of emergency care, diagnosis of coagulopathies
requires quick diagnostic tools [2]. For effective diagnosis and treatment of chronic
diseases such as cardiovascular diseases, certain biomarkers, such as blood viscosity, need
to be routinely monitored, therefore diagnostic tools that require small sample volumes that
can be carried out at the point-of-care show great potential [3].

1.2 Microfluidic Technology
Microfluidic technology, or lab-on-a-chip devices, manipulates miniscule amounts
of fluids [4]. Microfluidic technology has emerged rapidly in various fields ranging from
medical diagnosis to chemical synthesis [5]. At the microscale, gravitational forces are
greatly reduced and other forces such as capillary forces, surface tensions, and viscous
forces become more dominant [6]. The efficient transport of reactants within a miniaturized
device allows for faster diagnosis, resulting in a decrease in cost, on-site testing and
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diagnosis [5]. Droplet-based microfluidic systems generate a large number of isolated
volumes via emulsions of two or more immiscible phases allowing each individual droplet
to perform a different reaction from another droplet, therefore enabling parallel processing
and multiplexing of reactions without significantly increasing device size or complexity
[7]. A novel aspect of droplet microfluidics is the ability to produce uniform droplets at a
high throughput without material exchange between droplets [7]. On-site testing using
small sample sizes such as those from droplets would potentially allow for obtaining
continuous blood viscosity data from patients, thereby improving diagnosis and treatment
accuracy [5]. Microfluidic devices are revolutionizing the field of medical diagnosis by
providing patients and healthcare providers with point-of-care diagnostic tools [8]. The
integration and automation of the lab-on-a-chip systems remain as major challenges to their
wide-spread adoption in many biological fields [5, 8].

1.3 Blood Coagulation
There are three pathways that make up the blood coagulation pathway: the intrinsic,
extrinsic, and common pathway (Figure 1.3.1). Each of these pathways is governed by

Figure 1.3.1 Clot formation: A diagram
of clot formation.
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biochemical interactions and coagulation factors [9]. A bleeding disorder is typically
associated with the deficiency of one of the coagulation factors [10]. For instance, when
tissue damage occurs, blood begins to clot to plug up the damaged tissue. First, clotting
factors are released in response to an injury, followed by vasoconstriction of the blood
vessels to limit blood flow and platelets form a plug. Then fibrin strands attach to the plug
and form a clot. Conventional tests do not provide a global assessment of hemostatic
function and biochemical processes that play a role during the clot formation process [11,
12]. Viscoelastic hemostatic assays provide better insights into the coagulation cascade as
it is performed with whole blood.

1.4 Conventional Coagulation Tests
Bleeding disorders are routinely diagnosed by a panel of conventional coagulation
tests, or CCTs [2, 11, 12]. CCTs are widely used in clinical settings to assess blood clotting
function and can be extremely useful for identifying and characterizing bleeding disorders
of secondary hemostasis [13]. The typical tests in a CCT panel include Hemoglobin
concentration (Hb), hemocrit, platelet count, fibrinogen level, prothrombin time (PT),
activated partial thromboplastin time (aPTT), international normalized ratio (INR), and Ddimer. In these tests, blood samples are treated in vitro with an array of activation factors
to measure the coagulation time [13, 14]. For example, prothrombin time is a plasma-based
assay that evaluates the extrinsic and common pathways (specifically factors VII, X, V, II,
and fibrinogen) where calcium and thromboplastin, a tissue factor and platelet
phospholipids, are added to blood plasma to initiate the fibrin clot formation [9, 15]. The
typical time to fibrin gel formation for PT is approximately 10-14 seconds [16].
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Prolongation of the PT usually implies a defective extrinsic and/or common pathways [17].
An aPTT test evaluates the intrinsic and common pathway where calcium, platelet
phospholipids, and an activator (silica, celite, kaolin, or ellagic acid) are added to blood
plasma to determine the clotting time in the absence of tissue factors [18]. The typical time
to fibrin gel formation for aPTT is typically 20-50 seconds and prolongation of the aPTT
indicates defective intrinsic and/or common pathways.
The panel of CCTs, however, have numerous limitations as well [19]. For instance,
CCTs do not measure the balance of the hemostatic components through all phases, from
clot initiation through clot lysis and only provide end point measurements [2, 12, 20, 21].
They also do not account for the balance between coagulation and fibrinolysis, and
therefore, are not sufficient to explain the pathways leading to hemostasis in vivo [20].
CCTs are limited in detecting the type of hypercoagulation and the shortening of PT/aPTT
time is not a consistent predictor of hypercoagulability [12, 14, 22]. These tests cannot
identify the root cause for certain bleeding disorders, especially induced coagulopathies or
trauma-induced coagulopathies [22-25]. CCTs in general, and in vitro plasma-based tests
such as PT and aPTT in particular, do not account for important interactions between
molecular and cellular components (e.g. platelets, fibroblasts and clotting factors) in
platelet activation and thrombin generation, as they are based on the cascade model of
coagulation [26, 27]. Further, PT/aPTT tests do not assess overall strength and stability of
clots as they are measured at the initiation of fibrin polymerization [12, 20, 21]. PT/aPTT
do not detect hyperfibrinolysis or platelet dysfunction and are not prolonged until
fibrinogen falls to very low levels [28]. CCTs are not point-of-care assays and long
processing times can lead to treatment delays which is associated with mortality and
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morbidity, especially under time-constrained circumstances such as trauma and surgery [2,
23, 29, 30]. Therefore, when CCTs fall short in providing sufficient diagnostic information,
Viscoelastic Hemostatic Assays are performed to gain more insight into global hemostatic
function.

1.5 Viscoelastic Hemostatic Assays
Viscoelastic hemostatic assays, or VHAs, deliver an effective solution to the
diagnostic testing of coagulopathies by evaluating global hemostatic function using whole
blood rather than plasma [2, 12, 14, 21, 31]. VHAs are functional blood tests that monitor
all phases of coagulation by measuring the viscoelastic properties of blood during clot
formation and degradation to help determine the root cause of bleeding [12]. The current
commercialized VHA methods are the Thromboelastometry (TEM) and the
Thromboelastography (TEG). These two instruments, however, have a high acquisition
cost, bulky benchtop size, and are mostly limited to use in surgical procedures [32]. Here,
I demonstrate a proof-of-concept device which can potentially be developed into
microfluidic viscoelastic hemostatic assay (µVHA) to facilitate point-of-care hemostatic
tests using a method based on digital microfluidics where whole blood samples are
partitioned into nanoliter sized emulsion droplets. These portable and low cost µVHAs
would reduce the footprint and overall cost of analytical systems, broaden potential
applications beyond emergency and surgical procedures and would enable field/combat
medics providing frontline trauma and medical care to deployed personnel [2, 4, 8, 14, 21].
VHAs provide a point-of-care global and functional assessment of hemostasis by
revealing contributions and interactions of all hemostatic components during clot
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formation [12, 20]. Viscoelastic properties of the blood clot are evaluated starting at
initiation of coagulation through amplification and propagation of the clot to fibrinolysis
[12, 32]. VHAs help determine the root cause of bleeding and evaluate how fibrinogen
forms fibrin [33]. Fibrin is an insoluble protein that is responsible for forming blood clots.
It forms a fibrous mesh that will impede the flow of blood. VHAs enable diagnosis of both
inherited and acquired bleeding disorders, including post-traumatic coagulopathies and
mechanisms underlying traumatic hemorrhage, are often used as a diagnostic tool to guide
patient-specific transfusion therapy [29, 34-36]. VHAs have several advantages over the
typical panel of conventional coagulation tests, or CCTs, including providing an overview
of global hemostatic function. First, they provide information on all phases of hemostasis,
including initial fibrin formation, fibrin-platelet plug construction, and clot lysis [2, 12].
Second, VHAs are also capable of diagnosing hypo-coagulable conditions that are not
evident with CCTs. They facilitate rapid diagnosis of coagulopathies and reduces overall
transfusion requirements [20]. VHAs have been proven superior in predicting and
diagnosing coagulopathies, guiding transfusion therapy, and found clinical applications in
cardiac surgery, liver transplantation and obstetric hemorrhage [22, 35-38]. In cardiac
surgery, where the risk of surgical bleeding or induced coagulopathy is higher, VHAs can
help identify patients needing peri operative (mid-operation) or postoperative (after
operation) transfusion therapy [27, 36, 37]. Transfusion therapy guided by VHAs reduces
the frequency of blood product transfusions (red blood cells and platelets) and major
bleeding following cardiac surgery [34, 39]. The advancements in VHAs will allow for
point-of-care testing which yields quicker results and enables wider adoption of the method
in emergency and operating rooms [12, 40]. Specifically, VHAs lead to cost-effective
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practices for trauma and cardiac surgery patients in comparison to typical CCTs [39, 41].
Closely mimicking the major physiological processes of hemostasis in vitro helps
providing insights into the root cause of bleeding disorders where plasma-based
conventional coagulation tests (PT, aPTT, INR) have limitations in detecting impaired
hemostasis [24, 27, 41].
Even though VHAs provide several advantages over the panel of CCTs that are
usually used to diagnose coagulation disorders, they still have some limitations. Due to
their bulky instrumentation size and high price tag, their implementation is currently
limited to patients with trauma or undergoing surgical procedures [23]. The commercial
VHA instruments are mainly used in operating rooms and emergency care units [40]. Their
use in medical procedures is also limited to a few procedures including transfusion therapy,
liver transplant, trauma, and cardiac surgery [23, 37, 38]. To increase the versatility and
wide-spread adoption of VHAs in the biomedical field, improvements in blood sample
handling, full automation of the assay protocols, simultaneous testing with multiple
activators, integrated analysis software and enhancing robustness of the device are needed
[2].

1.6 Thromboelastography and Thromboelastometry
Two of the most common VHAs on the market today are the Thromboelastography
(TEG) and the Thromboelastometry (TEM). The TEG was first described in 1948 by
Hartert who measured the viscoelastic changes of whole blood during coagulation under
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A

B
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Figure 1.6.1 Major commercialized VHA systems: (A) An image of a
commercial thromboelastometry (TEM) system. The schematic of (B) the
TEG system and (C) the TEM system. Component 1 represents the cup, 2
represents the blood sample, 3 represents the pin, 4 represents the transducer
(optical/electrochemical) and 5 represents the data processing unit (Adapted
from [20]).
low shear conditions [42]. He developed a graphical representation of the rate of fibrin
polymerization and the overall clot strength, although the technique was not adopted for
clinical use until the 1980s [3, 32]. The TEM was developed in 1995 as an enhancement
for hemostasis testing in whole blood, providing differential diagnostic information [3, 32].
Both processes rely on a transducer that measures clot firmness as a function of time where
300uL whole blood is placed into a cylindrical cup at 37 degrees Celsius [3, 12, 32]. A
suspended pin is inserted into the cup, and the viscoelastic properties of blood clots are
deduced by monitoring changes in the rotation of the pin (Figure 1.6.1). The pin is not in
direct contact with the cup and the blood sample provides the physical link between the
cup and the pin (Figure 1.6.1b-c). Coagulation activators are then added to the sample and
coagulation is triggered by oscillating either the cup (TEG) or the pin (TEM) back and
forth around the vertical axis [3, 12, 32]. The torque acting on the pin due to rotation is
minimal at the beginning of the process. As the blood coagulates, the blood sample starts
forming a clot between the cup and the pin which generates a torque proportional to clot
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firmness which is transmitted to the pin. The pin is connected to a detector system which
measures torque applied to the pin. In the TEG, the detector system is a torsion wire and in
the case of TEM, it is an optical detector [2, 3, 12, 32]. The strength of the formed clot is
measured with an electromechanical (TEG) or an optomechanical (TEM) transducer during
the coagulation process. The TEG and TEM curves produced from the process show clot
firmness as a function of time.
The transducer data collected from the coagulation process are converted into
TEG/TEM curves displaying clot firmness as a function of time (Figure 1.6.2a). From these
curves, we can deduce the parameters representing characteristics of coagulation and the
lysis process [2, 3, 12, 32]. The key parameters for a TEG curve include reaction time (R),
kinetics (K), maximum amplitude (MA), clot lysis (CL), and the slope of K and 𝛼 (alpha).
The key parameters for a TEM curve include clotting time (CT), clot formation time (CFT),
maximal clot firmness (MCF), lysis (LY), and the slope of the tangent at 2mm amplitude
(𝛼). Reaction time, or clotting time, represents the time of latency, the time from the start
of the test to the initial fibrin formation and is typically between 15 and 23 minutes [2, 3,
12]. Kinetics, or clot formation time represents the time to achieve a certain level of clot
strength and is typically between 5 and 10 minutes. The maximum amplitude, or maximal
clot firmness, is a function of the dynamic properties of fibrinogen and represents the
ultimate strength of the clot before it starts to degrade. The alpha angle (𝛼) measures the
fibrin build-up and cross-linking speed, assessing the clot formation speed. The curves are
divided into parts that reveal different successive stages of the hemostatic process, from
initiation of coagulation to fibrinolysis. The typical TEG/TEM for a healthy patient shows
a coagulation trace in the shape of a horizontal champagne flute. Anomalies seen in the
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TEG/TEM curves are used to diagnose inherited or acquired bleeding disorder (Figure
1.6.2b). In the presence of a coagulopathy (a coagulation disorder), the shape of the
coagulation trace is modified, hinting at the root cause of coagulopathy [2, 3, 12]. The
shape of the TEG/TEM curves can be analyzed to associate them with specific
coagulopathies and then develop patient-specific therapies. For instance, hypercoagulation
is diagnosed when reaction time (R) or clotting time (CT) is shortened; kinetics (K) or clot
formation time (CFT) is also shortened; max amplitude (MA) or max clot firmness (MCF)
is increased. Another example includes hemophilia where coagulation trace features show
longer reaction time (R) or clotting time (CT), longer kinetics (K) or clot formation time
(CFT), and smaller max amplitude (MA) or maximum clot firmness (MCF). Using the
process of creating the TEG/TEM curves and deriving the key parameters from those
A

B

Clot
formation
time

Figure 1.6.2 Viscoelastic Hemostatic Assay
(VHA) as a diagnostic tool: (A) Typical
coagulation traces generated by TEG and
TEM and expressed as clot firmness as a
function of time. R and CT representing the
reaction time to start clotting. MA and MCF
representing the maximum clot firmness, and
LY and CL representing clot lysis. (Adapted
from [20]) (B) TEG/TEM traces can be used
to diagnose acquired or inherited bleeding
disorders and help guide patient-specific
transfusion therapy (Adapted from [3]).
Clot
firmnes
s

Normal Coagulation
Trace

Blood Thinners:
Elongated
coagulation time
Smaller clot
firmness
Clotting factors:
Shortened
coagulation time
Larger clot firmness
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curves, it is possible to use anomalies in the curves to diagnose inherited or acquired
bleeding disorders [23].
Even though the TEG and TEM are valuable tools for diagnosing inherited or
acquired bleeding disorders, they do have some limitations. Both systems have a high
acquisition cost. The TEG that is commercialized by Hemoscope Corporation, which is
currently a subsidiary of Haemonetics, and its two-channel TEG 5000 system costs over
$18K. The ROTEM delta, a four-channel rotational TEM system developed by TEM
International GmbH (now part of Werfen) costs nearly $28K. The cost of running a “basic
test” is about $10 and the platelet function test costs about $90. Finally, their bulky
benchtop size limit widespread use of commercial TEG/TEM systems, mainly restricting
their use in surgical procedures [1, 2].

1.7 Microfluidic Viscoelastic Hemostatic Assays (μVHA)
In this work, we propose to develop a microfluidic viscoelastic hemostatic assay
(μVHA), a more accessible and low-cost diagnostic tool to facilitate point-of-care
hemostatic tests. Our method is based on digital microfluidics where whole blood samples
are partitioned into nanoliter sized emulsion droplets [1, 2, 43, 44]. These portable and low
cost µVHAs would reduce the footprint and overall cost of analytical systems, broaden
potential applications beyond emergency and surgical procedures. Our approach would
enable development of field deployable platforms that can be utilized by military medics
in trauma care immediately after injury to determine course of action and increase the
effectiveness of treatment. Utilizing a digital microfluidic approach and implementing an
optofluidic method to generate coagulation traces, it will transform the existing VHA
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methods based on electromechanical or optomechanical transduction by mitigating its
shortcomings and potentially extending its applications in biomedical fields [20, 39]. The
µVHA is based on an established microfluidic technology, digital microfluidics, which
involves generation and manipulation of nanoliter sized droplets within microchannels [7,
45]. Blood samples are partitioned into droplets using a flow-focusing geometry by
squeezing the sample stream by two orthogonal immiscible carrier fluid streams at a
microfluidic junction where the stream is broken into monodisperse nanoliter sized droplets
[7, 46]. During the emulsification process, droplet size and inter-droplet distance is dictated
by the device and flow parameters such as device geometry (channel height, widths, and
lengths), absolute and relative flow rates of sample fluid (e.g. blood) and immiscible carrier
fluid, and the relative viscosities of the sample and carrier fluids [1, 43, 44, 47]. Droplet
size and inter-droplet distance during droplet breakup process can be used to monitor
changes in sample fluid viscosity [43]. For a given device geometry and sample-to-carrier
fluid flow rate ratio (𝑄! /𝑄" ), the droplet length decreases as the viscosity of the sample
fluid increases [43]. As the coagulation process proceeds, the viscosity of the blood
increases which leads to a reduction in droplet length [44]. In this manner, using the
correlation between viscosity and droplet length, the viscosity of the blood can be actively
monitored as a function of time during the coagulation process. Dynamic blood viscosity
measurements during coagulation process allows for generation of clot firmness curves
that are obtained through conventional VHA methods including TEG and TEM. Our goal
is to develop a proof-of-concept, portable microfluidic VHA (μVHA) to generate
coagulation traces throughout the coagulation process, similar to those from the TEG/TEM,
for rapid and accurate diagnosis of bleeding disorders.
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1.8 Novelty of our Approach
The novelty of our approach is based on an innovative engineering tool, digital
microfluidics, to enhance the status quo in coagulation monitoring by providing an
enabling new technology for rapid diagnosis of bleeding disorders. The device will be an
automated, droplet-based method for real-time monitoring of whole blood coagulation in
vitro. Viscoelastic properties of whole blood during clot formation and degradation will be
monitored using an optofluidic method. A microfluidic approach enables reduction of the
sample size by a factor of 3, down to 100uL, and allow for parallel testing of various
versions of VHAs using a single blood sample [2]. Reduction of the sample size and
parallel testing potentially opens new applications of coagulation monitoring in point-ofcare testing [26, 38, 48]. For instance, reducing the sample size below 100μL could extend
the application of VHAs to pediatric procedures [49]. The microfluidic system will shrink
the overall size of the coagulation monitoring instrument, therefore reducing the cost and
increasing portability [43, 50]. Mixing of the coagulation initiators will be automated
which will minimize human errors encountered in TEG/TEM-based assays, improving
reliability and robustness of viscoelastic coagulation assays [44, 51]. This method will also
have the ability to measure non-Newtonian fluids and will be readily applicable to measure
viscoelastic properties of other limited-volume biological samples such as cerebrospinal
fluid, pleural fluid, and amniotic fluid for diagnostic purposes [52].
In μVHA, coagulation process and clot stiffness are monitored by quantitatively
analyzing the droplet breakup process; and coagulation traces similar to the TEG/TEM
systems are generated The slope of the linear relationship between the sample and the
quantity given by 1/(𝐿* − 𝐿) ) determines the sensitivity and the range of viscosity
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measurements. This slope can be adjusted by the device and flow parameters such as
channel dimensions, carrier fluid viscosity, absolute and relative flow rates of blood and
immiscible carrier fluid [43, 44]. As the ratio of the sample flow rate to the carrier fluid
flow rate (𝑄! /𝑄" ) increases, the sensitivity of measuring the viscosity measurements
increases [43]. The range and sensitivity of the viscosity measurements can be tuned
towards a specific application by adjusting the device geometry and flow parameters [43].
Our method relies on generating coagulation traces similar to the TEG/TEM
systems by analyzing the droplet size and inter-droplet distance during the droplet breakup
process. Using the coagulation traces, it is possible to derive fundamental parameters
characterizing the coagulation process such as clot formation time, maximal clot firmness,
and clot lysis. This requires extensive analysis of how microfluidic device geometry and
flow parameters affect the generation of coagulation traces. Initially, the focus will be on
testing samples from healthy individuals to demonstrate the applicability of the method to
monitor coagulation using normal blood samples. To test the validity of our approach, the
µVHA devices will be tested using samples from healthy individuals that are spiked with
inhibitors and thrombin to mimic and hypercoagulable state with excessive blood clotting.
The results will be compared against those from the TEG and TEG systems to illustrate the
feasibility of this device towards the diagnosis of bleeding disorders.
Our approach has the potential to widen the adoption of VHAs by clinicians in
procedures where blood loss or bleeding disorders have to be evaluated in the diagnostic
and therapeutic decision-making process. The small size of the device will help reduce the
footprint and overall cost the system, therefore broadening the potential applications of
VHAs in medical practices beyond emergency and surgical procedures. The proposed
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method will reduce the sample size three times, enable automatic fluid handling, increase
the multiplexing capability by allowing more assays to run simultaneously in parallel, and
substantially shrink the footprint of the instrumentation to enable portable and/or fielddeployable devices [53].
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Chapter II
Microfluidic Viscoelastic Hemostatic Assay for Real-Time
Viscosity Measurements

2.1 Introduction
Viscosity of chemical and biological fluids is an important materials property. In
medical diagnostics, changes in physical and chemical properties of biofluids can be
correlated to a number of diseases. Laborious procedures, high testing cost and larger
sample sizes are typical limitations associated with continuous viscosity measurements
and, therefore, characterization of viscosity is often limited to end-point measurements
[50]. Miniaturized viscometers can be developed using microfabrication and microfluidic
technology, and the incorporation of droplet microfluidics can further reduce sample size
from microliters to nanoliters [43, 47, 50, 51]. Here, we report a continuous droplet-based
viscometer to measure viscosity of aqueous fluids based on the size and length of
emulsified droplets generated under constant pressure.
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2.2 Device Design
We tested several designs for our microfluidic viscometer and the final version
comprised of one oil inlet, one aqueous solution inlet and one outlet (Figure 2.2.1).

Constriction

1.5mm

4.8mm

4mm

70um
40um

1.5mm
1mm

Oil
Inlet

7.2mm

Blood
Inlet 9.4mm

8mm

8mm

Outlet

Figure 2.2.1 Microfluidic viscometer device design: We
designed a microfluidic device consisting of one oil inlet, one
aqueous solution inlet and one common outlet channel. The length
of the oil inlet, aqueous inlet, and outlet channels were 50.2mm,
7.2mm and 8mm, respectively. Droplets are generated at a junction
where the oil and aqueous inlets meet. The channel width and
height across the device was 100 and 50 µm, respectively. The
aqueous inlet and the outlet channel contained a 40µm wide and
70µm long constriction at the junction.
Mask Design:
The device designs were created using AutoCAD software. The device geometry was
inspired by Li et. al. [43, 44]. The device consists of a droplet generator using a flow
focusing geometry where a microchannel carrying the aqueous sample solution meets a
perpendicular channel at a microfluidic junction. At this junction, the aqueous sample is
split into droplets by two opposing streams of immiscible oil. The oil inlet was split into
two channels which has a total length of 50.2 mm up to the microfluidic junction where it
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meets with the sample/aqueous inlet. The length of the aqueous/sample channel was 7.2
mm. Droplets generated at the microfluidic junction were carried down an 8 mm long outlet
channel. All channel widths were 100 µm. At the microfluidic junction, the
aqueous/sample channel and the outlet channel had a 40 µm wide constriction, which
facilitated droplet generation. Channel height was approximately 50 µm which was
determined by the thickness of the SU-8 during photolithography process. The dimensions
of this device are shown in Figure 2.2.1.

2.3 Device Fabrication
The device is fabricated by conventional photolithography and soft lithography techniques
[54] (Figure 2.3.1).
Cleanroom Procedures:
Gowning:
Photolithography

A special gown including a

Mask

UV Light

coverall, shoe covers, boots,
Mas
SU-8 (negative photoresist)

SU-8

Si wafer

Si wafer

UV Exposure

UV

Soft Lithography

Soft

After
PDMS

SU-8

Channel

Si wafer

Glass Slide

PD

must

be

worn

when

After Development

PDMS

PDMS Casting

hair net, hood and gloves

fabricating the devices in the
cleanroom to minimize dust
and contamination.

Peel, Punch, and Bond to a Glass
Slide

Peel,
Figure 2.3.1 Device fabrication: Punch,
Fabrication process of

microfluidic devices with photolithography and soft
lithography.
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SU-8 Coating:
Silicon wafers were cleaned
using acetone and isopropyl

alcohol and dried off with compressed dry air. The wafers were then placed on a hot plate
(Torrey Pines EchoTherm HS40A) at 65 degrees Celsius to remove any surface water.
After cleaning, the wafer was carefully placed on the spin coater (Laurell, WS-650Mz23NPPB), centering it to the chuck. Prior to spin coating step, the wafer was secured to the
chuck by turning on the vacuum. A small amount of SU-8 2050 was dispensed onto the
wafer such that the photoresist covered about 2/3 of the wafer. Any bubbles in the
photoresist were carefully removed using a plastic disposable pipet. We then run the
following program to spin coat the wafer with the photoresist:
1.) Spin at 500 rpm for 5-10 seconds with acceleration of 100 rpm/second.
2.) Spin at 2000 rpm for 30 seconds with acceleration of 300 rpm/second.
This procedure typically yields 50 µm thick device features on the SU-8 mold. During spincoating, a build-up of photoresist, called edge bead, can occur on the edge of the substrate.
A swab dipped in acetone can be used to wipe the edge of the wafer to minimize its impact
on photomask contact during the lithography step. We then performed a soft bake step, 3
minutes at 65°C and 9 minutes at 95°C, as suggested by the manufacturer.
Exposure:
To obtain vertical sidewalls with SU-8 2050, a long pass filter was used to eliminate UV
radiation below 350 nm. The wafer was placed under the UV flood exposure unit (350W
Model LS-150-3 NUV Exposure System, Bachur Associates) and the desired mask was
placed on the wafer, a quartz slab was then placed on top of the wafer to bring the mask
and the wafer into conformal contact. The wafer was then exposed to UV light for
approximately 11 seconds.
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Post Exposure Bake:
The wafer was baked for 1-2 minutes at 65°C, then for 6-7 minutes at 95°C. After 1 minute
of baking at 95°C, an image of the mask was visible in the photoresist. If no visible latent
image is seen during or after PEB, the exposure, post-baking (or both) was insufficient.
Development:
We immersed the wafer to the solvent-based developer, PGMEA, for 7 minutes. The
development times are approximate, since actual dissolution rates can vary widely as a
function of agitation. While immersed, the wafer was agitated to fully remove any
uncrosslinked SU-8. If successful, no white streaks should appear on the wafer. The wafer
and SU-8 features should look clean and transparent.
Rinse and Dry:
The mold was then rinsed with isopropyl alcohol 3-4 times and dried with compressed dry
air. The mold was then stored within a petri dish in the cleanroom.
Hard Baking (optional):
SU-8 has good mechanical properties, therefore hard bakes are normally not required.
When cracks were observed in the device features, we hard-baked the wafer by gradually
ramping the temperature up to 150°C, baking at this temperature for 5 minutes, then
cooling it down to room temperature.

PDMS Chip Fabrication:
PDMS Preparation:
To prepare the wafer for replica molding, the wafer was silanized by adding a few drops
of silane into a petri dish, then incubating under vacuum for 15-30 minutes. PDMS was
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prepared by mixing the base and the cross-linker component at a 10:1 (by mass) ratio. The
two were mixed together in a plastic cup and degassed using a vacuum desiccator. The
PDMS mixture was then poured onto the wafer in the petri dish. The wafer was placed into
an oven at 75 degrees Celsius for a minimum of two hours.
Preparing the final device:
After taking the PDMS wafer out of the oven, it was left to cool down to room temperature.
Then, using a scalpel, the PDMS layer was carefully cut out of the petri dish. Holes were
punched into the PDMS to form the inlet and outlet ports for each device.
Cutting:
Using a razor blade, the PDMS slab was cut into sections that will fit onto a glass slide.
Depending on the size of the devices, there could be many devices on a PDMS slab that
can fit on one slide. We typically obtained two devices per 1x3” microscope slide.
Bonding:
The PDMS slabs were cleaned by adhesive tape to remove any dust particles and PDMS
fragments from punching inlet and outlet ports. The PDMS slabs and clean glass slides
were placed into the chamber of a plasma cleaner (Harrick Plasma PDC-001) and exposed
to oxygen plasma at a power of 30W for approximately 20 seconds. The PDMS slabs
containing microfluidic device features should face-up on the glass tray. After plasma
activation, the PDMS and glass slide were brought into conformal contact to obtain a
complete device. The bonded devices were put into a petri dish and baked at 75 degrees
Celsius overnight.
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Silanization:
Prior to each experiment, we silanized our microfluidic devices using Aquapel (PPG
Industries). Briefly, aquapel solution was transferred into a 1mL glass, gas-tight syringe,
and the solution was introduced into the oil inlet port. The device was carefully filled with
the Aquapel solution. 8-10 devices were treated at one time, allowing each device to be
exposed to Aquapel solution for approximately 30-60 seconds. Next, using an empty
syringe, air was pushed through each device to expel the Aquapel solution and dry the
device. A second syringe with ethanol was used to wash the devices and remove any
residual Aquapel. Subsequently, the empty syringe was used again to flow air through the
devices to remove ethanol. The devices were then baked at 75 degrees Celsius for at least
20 minutes.

2.4 Experimental Setup:
The experimental setup consisted of a microfluidic device, an inverted microscope,
a CCD camera, two electronic pressure regulators and a computer (Figure 2.4.1). The
microfluidic chip was mounted onto the microscope (Nikon TS100) stage with a 4x
objective lens, and images and videos were captured with a CCD camera (Basler acA800510um). The glass slide was secured to the stage using tape to keep the device in focus
during the experiment. 2 mL of the aqueous solution was transferred into a glass vial with
a screw cap with precision-fit silicone and PTFE septum providing a leak-proof seal. The
oil solution (Light mineral oil, Fisher Scientific) was also transferred into a similar
container. Polymer tubing (Saint-Gobain Tygon Tubing, ND-100-80, .020" ID x .060" OD)
with a metal tubing (New England Small Tube, NE-1310-03) at each end was used to
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Figure 2.4.1 Experimental setup for microfluidic viscometer: (A)
Schematic of the experimental setup (B) Micrograph of droplet generation at
the microfluidic junction (C) an image of the microfluidic device mounted
on the microscope. (D) Image of droplets produced by the device in the outlet
channel.
introduce fluids for each inlet. One end of the tubing was inserted through the septum of
the vial and the other end, bent at a ninety-degree angle, was inserted into the device. Each
inlet and outlet tubing is inserted into the device in a similar manner. Compressed dry air
was

fed

into

an

electronic

pressure

regulator

(ProportionAir,

MPV1MBHEEZP30PSGAXL) to control air pressure through each inlet (Figure 2.4.1).
Compressed dry air through the pressure regulator is connected to the vials containing the
aqueous sample and the oil. The electronic pressure regulator was controlled by a custom
LabVIEW code, where the magnitude of air pressure for both solutions was adjusted within
0-30 psi. The same device was used for conducting viscosity measurements for different
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solutions. Between each measurement, the device was flushed by compressed dry air.
Droplet images were captured along the outlet microchannel at a position just below the
microfluidic junction. Droplet images were analyzed and droplet parameters including
droplet length were extracted using ImageJ and MATLAB.

2.5 Solution Preparation
Aqueous Solutions:
Blood viscosity ranges within 0-60 cP at medium shear rates (80-100 sec−1) for healthy
individuals [55]. We prepared aqueous glycerol solutions ranging from 1 to 60 cP to mimic
various stages of blood coagulation and used these solutions as the aqueous phase for the
droplet generation. The solutions were created by mixing water and glycerol as given
below, and the viscosity values were confirmed by a commercial rotational viscometer
(Brookfield LVDV-II+CP). We prepared the glycerol solutions using a table reporting
viscosity of glycerol and its aqueous solutions at various % weight (Table 2.5.1). We
confirmed viscosity of each sample solution using a cone and plate viscometer (Figure
Glycerol (% weight)

Viscosity (cP) @ 20ºC

0

1.005

20

1.76

50

6

60

10.8

values

70

22.5

solutions. We further

75

35.5

80

60.1

Table 2.5.1: Viscosity and % weight of aqueous glycerol
solutions mimicking various stages of blood coagulation
used in the experiments.
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2.5.1). Our results are
in good agreement with
the tabulated viscosity
for

glycerol

measured the viscosity
of

a

human

blood

sample with the rotational viscometer and found out that the blood viscosity was
approximately 9.75cP.
Oil Solution:
For the oil phase, we used light mineral oil (CAS 8042-47-5, Fisher Scientific). To facilitate
droplet generation, 10% Silube (T308-16, Siltech Corporation) was added to the oil phase
as surfactant.

Figure 2.5.1 Viscosity measurements of glycerol solutions using a
commercial cone-and-plate viscometer: The plot displays expected
viscosity values for glycerol solutions shown in Table 2.5.1 versus the
viscosity measurements performed with a rotational viscometer. The
red star in the figure represents viscosity measurement for a human
blood sample.

25

2.6 Measurements
Using the LabVIEW program, the air pressure was regulated to flow oil and
aqueous solution through the device (Figure 2.6.1). Droplets were formed at the junction
where the aqueous phase was pinched by the oil phase. Flow rates through the inlets are

Figure 2.6.1 Experimental setup control: (A) Image of the microfluidic junction as
observed during experiments and (B) the LabVIEW interface used to control flow
with the pressure regulator.

A 6psi(aq) – 11psi(oil)

B

100um
C

Figure 2.6.2 Streamlined image
processing to extract droplet
parameters: (A) Droplet images
from an aqueous solution of 1cP at
an inlet pressure of 6psi (aqueous
solution) and 11psi (oil). (B)
Thresholded droplet images (C)
Image stack was then analyzed to
detect individual droplets.
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controlled by individually adjusting the pressure applied to each inlet. For efficient droplet
generation, the oil phase should have a higher flow rate compared to the aqueous phase.
Using a CCD camera, we acquired videos of droplet formation for two minutes at the
beginning and end of an experimental run. In between videos, images were captured every
second for ten minutes. Using ImageJ, images were converted into a stack and processed
to determine the average length of the droplets (Figure 2.6.2). Briefly, droplet images were
first converted into stacks. The 8-bit images were then thresholded for binary conversion.
Then, we ran particle detection algorithms in ImageJ to detect each droplet and extract its
key parameters including droplet length.

2.7 Results
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The droplet-based viscometer uses pressure driven flow of an aqueous glycerol
solution and mineral oil for droplet generation at a microfluidic junction and a
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downstream channel for droplet measurement. Oil and glycerol solutions are introduced
to the microchannels using various inlet pressures and the droplets are then dispensed
into a centrifuge tube via the outlet tubing. At the junction, the aqueous phase is pinched
by the two opposing oil streams and droplets form in the downstream outlet channel. The
size of the droplets depends on the flow rate of the aqueous and the oil phase, the higher
the ratio of oil to aqueous solution, the smaller the droplets become. Droplet size is also
directly related to the viscosity of the aqueous solution. At a fixed pressure ratio, the
length of the droplet is inversely related to the viscosity of the aqueous solution, as the
viscosity increases from 1cP to 60cP, the droplet length decreases. A calibration curve
was constructed to show a linear relationship between 𝜂$+ and 1/(𝐿, − 𝐿" ) (or an

B

A
100um

4psi(aq)-6psi(oil)

100um

4psi(aq)-8psi(oil)

D

C

100um

100um

4psi(aq)-11psi(oil)

4psi(aq)-13psi(oil)

Figure 2.7.2: Effect of AIP/OIP on droplet size: Images of droplets generated
using 1cP aqueous solution and light mineral oil. The aqueous inlet pressure
(AIP) is kept at 4psi, while the oil inlet pressure (OIP) is changed from (A) 6psi
to (B) 8psi to (C) 11psi to (D)13psi. As OIP is increased, where AIP/OIP
decreases, the droplet length decreases from (A) 417.98µm to (B) 195.64µm to
(C) 145.33µm to (D) 119.99 µm.
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inverse relationship between the droplet length and the aqueous phase viscosity) that can
be used to calculate sample viscosities (Figure 2.7.1).
To generate droplets, the device needs to be operated such that the ratio of the
aqueous inlet pressure to oil inlet pressure, denoted by AIP/OIP, is within a certain range.
We focused on finding this optimal ratio range for each aqueous sample viscosity and then
determining which AIP/OIP ratio would yield consistent droplets across viscosity values
within 1-60cP (Figure 2.7.2). When the AIP/OIP is below the optimal range, the oil
pressure is too high and causes the aqueous solution to retract back up the sample channel
and no droplets can be formed. When the AIP/OIP is above the optimal range, the aqueous
sample flow rate is too high, and it forms a stream, rather than generating droplets, that coflows with the oil phase as the oil flow is insufficient to pinch the aqueous phase. Within
A
C

B

Figure 2.7.3 Droplet length at various aqueous phase viscosities and
AIP/OIP ratios: Droplet length versus aqueous phase viscosity
demonstrating an inverse relationship. As the viscosity increases, the droplet
length will decrease at a given flow rate. (A) 1psi(aq)-2psi(oil), (B) 10psi(aq)30psi(oil), (C) 11psi(aq)-22psi(oil).
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the optimal range of AIP/OIP, the droplet size increases with increasing AIP/OIP (Figure
2.7.2). The optimal value of AIP/OIP ratio should be the highest AIP/OIP that still
generates a steady train of droplets without distortion. The sensitivity of the device to
measure changes in viscosity increases with the AIP/OIP ratio, as can be seen in the
viscosity versus droplet length curve (Figure 2.7.3). As the flow rate increases (while
keeping the aqueous to oil inlet pressure ratio constant), the slope of the viscosity versus
droplet length plot also increases, indicating an increase in sensitivity (Figure 2.7.3).
Optimal results were obtained at high flow rates. For instance, setting the aqueous inlet
pressure to 11psi and the oil inlet pressure to 22psi (AIP/OIP = 0.5) provided a wide
dynamic range with high sensitivity for viscosity measurements (Fig. 2.7.3c).
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Chapter III
Whole Blood Analysis

3.1 Introduction
Abnormalities in blood clot formation is a major cause of morbidity and mortality
worldwide. In emergency medicine, uncontrolled bleeding is a major cause of death that
can be prevented [30, 40]. Coagulopathy, acidosis, and hypothermia are often referred to
as the “trauma triad of death” [23, 30]. It is reported that about one-fourth of trauma patients
suffer from coagulopathy [56]. Coagulopathy is also a major complication of sepsis and
leads to rapid death with over 1 million cases of sepsis per year resulting in 250,000 deaths
[27, 57]. With early diagnosis and early intervention and treatment, deaths due to
coagulopathy can be prevented.
Non-Newtonian fluids, such as blood, are viscoelastic and their viscosities depend
on shear rate. To characterize the viscosity profile of a non-Newtonian fluids, there are two
types of viscometers, the cone-and-plate viscometers and capillary viscometers [50].
Rotational viscometers, such as the cone-and-plate viscometer, measure viscosity based on
a velocity-driven flow field while capillary viscometers use pressure-driven flow to
measure viscosity [50]. An advantage of the capillary viscometers is their ability to
simulate real flow in tubular channels, such as blood vessels.
Droplet-based viscometers demonstrate advantages over existing microfluidic
viscometers such as lower sample volume, higher potential for automation, continuous
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operation capabilities and device reusability [43, 44, 47]. However, the droplet-based
viscometer has not yet been proven to measure viscosities for all types of fluids, such as
non-Newtonian fluids and highly viscous fluids. In this research, we use previously
developed droplet-based viscometer methods and apply them to measure viscosities of nonNewtonian fluids.

3.2 Results
Using our microfluidic viscometer, we performed viscosity measurements with
human whole blood samples (Figure 3.2.1). Specifically, we introduced human whole
blood samples with anticoagulants through the aqueous inlet and generated micron-sized
droplets in mineral oil (Figure 3.2.1, top panels). We observed a similar trend with the
droplet breakup process. We compared the length of the droplets from the blood sample to
those from the aqueous glycerol solutions. We determined that droplet sizes for the blood

11(blood)-22(oil)

1(blood)-2(oil)

100um

11(aq)-22(oil)

2(blood)-7(oil)

100um

2(aq)-7(oil)

1(aq)-2(oil)

100um

100um

100um

100um

x
Figure 3.2.1: Droplet-based viscosity measurements of human whole blood
samples: Droplet images comparing blood sample (top panels) and corresponding
aqueous glycerol solutions (bottom panel). We observed that the average droplet
length from blood samples were similar to those from 10cP glycerol solution.
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sample closely matched the 10cP aqueous glycerol solution. Therefore, we concluded that
the viscosity of the blood sample is approximately 10cP at the shear rates (~20 s-1). To
further confirm this, we overlayed the data point obtained from the blood sample to the
calibration plot obtained using aqueous glycerol solutions (Figure 3.2.2). We observed that
the viscosity measurement for the blood sample lies on the droplet length vs. aqueous
viscosity plot at the same aqueous and oil inlet pressures (and the same corresponding
AIP/OIP). Viscosity of human whole blood samples range between 2-6 cP prior to
coagulation [55]. Our viscosity value suggests that: i) viscosity measurements have a strong

Figure 3.2.2 Blood viscosity measurements using microfluidic viscometer:
The same graph from Figure 2.7.3c with an added data point from the blood
experiments. The red star data point represents droplet length obtained from
the blood sample at the same flow rate, 11psi(aqueous)-22psi(oil). Data from
the blood experiments is in agreement with the data from the glycerol
solutions. Error bars represent standard deviation for each data point.

temperature dependence, and the sample temperature was not close to the ideal (37°C). ii)
Despite the presence of anticoagulants, the viscosity value was above the expected value
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due to partial coagulation. Finally, we plotted droplet length as a function of inlet pressure
ratio (AIP/OIP) for the human whole blood sample (Figure 3.2.3). As expected, we
observed that, the droplet length increases with increasing AIP/OIP ratio where the OIP is
kept constant. A linear fit as shown in Figure 3.2.3 can be used to determine the minimum
possible droplet length that can be generated for a given OIP value. Overall, we
demonstrated that our microfluidic viscometer can be used to determine the viscosity of
human whole blood samples.

Figure 3.2.3 Droplet length of blood samples as a function of
AIP/OIP: Droplet length increases as the aqueous inlet pressure
increases at a constant oil inlet pressure. As a result, droplet
length increases with the flow rate ratio.
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Chapter IV
Conclusion and Future Work

4.1 Conclusion
With our results, we have demonstrated the application of droplet-based
microfluidic viscometers towards continuous measurement of viscosities for diagnostic
analysis. Our approach provides a simple and low-cost method to detect viscosity changes
in biofluids. Our method offers additional advantages for biological applications where
samples are difficult to obtain or costly, particularly when continuous monitoring is
necessary. This droplet-based microfluidic viscometer can measure viscosity of Newtonian
and non-Newtonian fluids, including biological fluids. The pressure-driven flow and small
channel size make it an ideal device for monitoring blood viscosity in cardiovascular
applications.
Our droplet-based viscometer provides a simple way to measure viscosity using a
minute sample size. With a pressure or a vacuum source to drive fluids within the device,
the viscometer could be applied along with other microfluidic processes such as dropletbased polymerization reactions to measure viscosity, improve uniformity performance of
the products. The viscosity changes can be visualized and analyzed based on the length of
the droplets or be measured in real-time with an on-chip sensor. This viscometer can be
used to measure absolute viscosities at different shear rates or measuring viscosity changes
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at a constant shear rate during a reaction leading to viscosity changes to monitor
progression of biological reactions such as in blood coagulation.

4.2 Future Work
We demonstrated that our microfluidic device is capable of generating aqueous
droplets with viscosities ranging from 1 to 60 cP into a carrier oil medium. We used our
platform to measure viscosity of human whole blood samples. When conducting blood
experiments, the blood sample was stored in vacutainers containing anticoagulants. To
initiate clot formation, CaCl2 was added to the blood sample prior to loading on the
microfluidic viscometer. However, once the coagulant is added, the blood coagulation
begins immediately. The time that it takes for the sample to travel the distance between the
sample vial and the microfluidic junction where the droplets are formed, limits the accuracy
of the viscosity measurement. Future versions of μVHA could facilitate on-chip activation
of coagulation by automatic mixing of coagulation activators and enable multiplexing to
concurrently run multiple versions of VHAs [2, 44].In the future, we would like to explore
a device design that administers the coagulant on chip, thereby minimizing the risk for
undesired clot formation and potential clogging of the device (Figure 4.2.1). This design
comprises of two oil inlets, one inlet for blood, and one inlet for coagulant. In addition, the
design will include serpentine channels to allow for efficient on-chip mixing of the blood
and the coagulant prior to droplet generation. Our next step would be to explore whether
the coagulant can be mixed on chip. Ultimately, generating droplets through all stages of
clot formation would help generate clot firmness curves similar to those obtained by TEG
and TEM.
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In the future, our droplet-based microfluidic viscometer can be automated for pointof-care applications. Droplet parameters including droplet length and inter-droplet distance
could be automatically measured and analyzed, and viscosities can be displayed in realtime by incorporating on-chip electrodes enabling capacitive sensing (6). This viscometer
could also be expanded/adapted to measure viscosity of blood plasma, deformability of red
blood cells and kinetics of blood coagulation. By expanding the applications of the
viscometer, this device could benefit patients and healthcare professionals, including
emergency physicians, hematologists, surgeons, blood banks, and military medics.
However, for developing a lab-on-a-chip device capable of conducting all of these tests,
integration of components such as droplet generation, separation of whole blood into blood
cells and plasma, mixing of reagents with blood droplets to trigger blood coagulation, and
cell deformability assays are needed.

Outlet

Oil
Inlet

Squiggles to mix
blood and
coagulant

Blood Inlet
Junction of Blood
and Coagulant

Coagulant
Inlet
Oil Inlet
Figure 4.2.1 A future microfluidic viscometer design: An alternative
device design for enabling on-chip mixing of coagulants for future
experiments.
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